Mumbai, Jan. 24 -- Revenue growth during the quarter was driven by Finished Dosages (FD) segment in North America and Europe.

Profit before tax (PBT) jumped 32.36% YoY to Rs 202.23 crore during the quarter.

EBITDA stood at Rs 308.1 crore, registering the growth of 34% compared with Rs 230.3 crore in Q3 FY25. EBITDA margin improved to 22% in Q3 FY26 as against 20% in Q3 FY25.

For Q3 FY26, Finished Dosages, Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/CDMO contributed 76%, 11%, 11%, and 2% of revenue from operations, respectively.

Net debt stood at Rs 1,015.1 crore and Net debt to EBITDA at 0.91x in Q3 FY26.

Krishna Prasad Chigurupati, chairman & managing director of Granules Ind...